Clinical Trial Supply & Logistics Market Size, Share & Trends Analysis Report By Service (Logistics & Distribution, Storage & Retention), By Phase, By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2024 - 2030
Clinical Trials Supply & Logistics Market Growth & Trends
The global clinical trials supply & logistics market size is expected to reach USD 6.25 billion by 2030, registering a CAGR of 7.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in advanced technology and innovations in the clinical trial supply & logistics market, implementation of stringent regulations, and the rising demand for clinical trials due to the increasing prevalence of diseases such as the COVID-19 pandemic.
Initially, the COVID-19 pandemic negatively impacted the market due to disruption in the supply chain and a reduction in commercial airlines by the government to prevent the spread of the virus. However, the market soon recovered and started to grow significantly due to rising demand for the COVID-19 vaccine to prevent this disease. For instance, according to WHO, as of August 2, 2022, there are 169 vaccines in the clinical development stage and 198 vaccines in the preclinical phase.
There has been significant investment in supply chain management software by clinical trial supplies providers. Growing complexity in clinical trials and increased competition among market players are factors responsible for the adoption of new technologies in supply chain management. The need for software for inventory management, supply chain planning, and ancillary supply chain management is expected to grow, owing to the increasing adoption of new technologies by industry players.
Clinical Trials Supply & Logistics Market Report Highlights
- In service segment, logistics & distribution dominated the market in 2023 with a share of 25.33%. This is due to the rise in clinical trials due to COVID- 19 pandemic
- Based on phase, The phase III segment accounted for the largest revenue share in 2023
- Based on therapeutic area, cardiovascular diseases accounted for the fastest CAGR of 8.0% during the forecast period. This is due to the rise in the number of investments by market players for bringing novel and innovation to the market
- Asia Pacific is anticipated to register the fastest growth rate of 8.1% during the forecast period. This is due to low recruitment cost, region has access to a large and diversified patient pool, and favorable policies that make the region desirable for clinical trials
- Chapter 1. Methodology And Scope
- 1.1. Market Segmentation And Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Service Segment
- 1.1.1.2. Phase Segment
- 1.1.1.3. Therapeutics Area Segment
- 1.1.1.4. End use segment
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR’s Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List Of Primary Sources
- 1.11. List Of Abbreviations
- Chapter 2. Clinical Trial Supply & Logistics Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Services And Phase Snapshots
- 2.3. Therapeutic Area And End Use Snapshot
- 2.4. Competitive Landscape Snapshot
- Chapter 3. Clinical Trial Supply & Logistics Market Variables, Trends, & Scope
- 3.1. Market Segmentation And Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Technological advancements in supply chain
- 3.4.2. Increasing R&D investment by pharmaceutical and biopharmaceutical firms
- 3.4.3. Expansion of clinical trial sites
- 3.5. Market Restraint Analysis
- 3.5.1. Stringent regulation pertaining to logistics.
- 3.5.2. Counterfeiting of drugs
- 3.6. Clinical Trial Supply & Logistics Market Analysis Tools
- 3.6.1. Industry Analysis - Porter’s
- 3.6.1.1. Supplier Power
- 3.6.1.2. Buyer Power
- 3.6.1.3. Substitution Threat
- 3.6.1.4. Threat Of New Entrant
- 3.6.1.5. Competitive Rivalry
- 3.6.2. PESTLE Analysis
- 3.6.2.1. Political Landscape
- 3.6.2.2. Technological Landscape
- 3.6.2.3. Economic Landscape
- Chapter 4. Clinical Trial Supply & Logistics: Service Estimates & Trend Analysis
- 4.1. Service Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Clinical Trial Supply & Logistics Market By Service Outlook
- 4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
- 4.4.1. Logistics & Distribution
- 4.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 4.4.2. Storage & Retention
- 4.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 4.4.3. Packaging, Labeling, And Blinding
- 4.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 4.4.4. Manufacturing
- 4.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 4.4.5. Comparator Sourcing
- 4.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 4.4.6. Other
- 4.4.6.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- Chapter 5. Clinical Trial Supply & Logistics: Phase Estimates & Trend Analysis
- 5.1. Phase Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Clinical Trial Supply & Logistics Market By Phase Outlook
- 5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
- 5.4.1. Phase I
- 5.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 5.4.2. Phase II
- 5.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 5.4.3. Phase III
- 5.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 5.4.4. Phase IV
- 5.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- Chapter 6. Clinical Trial Supply & Logistics: Therapeutic Area Estimates & Trend Analysis
- 6.1. Therapeutic Area Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global Clinical Trial Supply & Logistics Market By Therapeutic Area Outlook
- 6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
- 6.4.1. Oncology
- 6.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 6.4.2. Central Nervous System (CNS) Disorders
- 6.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 6.4.3. Cardiovascular Diseases
- 6.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 6.4.4. Respiratory Diseases
- 6.4.4.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 6.4.5. Others
- 6.4.5.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- Chapter 7. Clinical Trial Supply & Logistics: End Use Estimates & Trend Analysis
- 7.1. End use Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. Global Clinical Trial Supply & Logistics Market By End use Area Outlook
- 7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
- 7.4.1. Pharmaceutical
- 7.4.1.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 7.4.2. Biologicals
- 7.4.2.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 7.4.3. Medical Devices
- 7.4.3.1. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- Chapter 8. Regional Business Analysis
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030:
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key Country Dynamics
- 8.5.1.2. Competitive Scenario
- 8.5.1.3. Regulatory Framework
- 8.5.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key Country Dynamics
- 8.6.1.2. Competitive Scenario
- 8.6.1.3. Regulatory Framework
- 8.6.1.4. UK Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.3. Spain
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.4. France
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.5. Italy
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.6. Denmark
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Competitive Scenario
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.7. Sweden
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Competitive Scenario
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.6.8. Norway
- 8.6.8.1. Key Country Dynamics
- 8.6.8.2. Competitive Scenario
- 8.6.8.3. Regulatory Framework
- 8.6.8.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. JAPAN
- 8.7.1.1. Key Country Dynamics
- 8.7.1.2. Competitive Scenario
- 8.7.1.3. Regulatory Framework
- 8.7.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Competitive Scenario
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Competitive Scenario
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7.4. South Korea
- 8.7.4.1. Key Country Dynamics
- 8.7.4.2. Competitive Scenario
- 8.7.4.3. Regulatory Framework
- 8.7.4.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7.5. Thailand
- 8.7.5.1. Key Country Dynamics
- 8.7.5.2. Competitive Scenario
- 8.7.5.3. Regulatory Framework
- 8.7.5.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.7.6. Australia
- 8.7.6.1. Key Country Dynamics
- 8.7.6.2. Competitive Scenario
- 8.7.6.3. Regulatory Framework
- 8.7.6.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key Country Dynamics
- 8.8.1.2. Competitive Scenario
- 8.8.1.3. Regulatory Framework
- 8.8.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.8.2. Mexico
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Competitive Scenario
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Mexico Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
- 8.8.3. Argentina
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Competitive Scenario
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.9. MEA
- 8.9.1. MEA Clinical Trial Supply & Logistics Market, 2018 - 2030 (USD Million)
- 8.9.2. South Africa
- 8.9.2.1. Key Country Dynamics
- 8.9.2.2. Competitive Scenario
- 8.9.2.3. Regulatory Framework
- 8.9.2.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.9.3. Saudi Arabia
- 8.9.3.1. Key Country Dynamics
- 8.9.3.2. Competitive Scenario
- 8.9.3.3. Regulatory Framework
- 8.9.3.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.9.4. UAE
- 8.9.4.1. Key Country Dynamics
- 8.9.4.2. Competitive Scenario
- 8.9.4.3. Regulatory Framework
- 8.9.4.4. UAE Market Estimates And Forecasts 2018 To 2030 (USD Million)
- 8.9.5. Kuwait
- 8.9.5.1. Key Country Dynamics
- 8.9.5.2. Competitive Scenario
- 8.9.5.3. Regulatory Framework
- 8.9.5.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company /Competition Categorization
- 9.3. Vendor Landscape
- 9.3.1. List Of Key Distributors And Channel Partners
- 9.3.2. Key Customers
- 9.3.3. Key Company Market Share Analysis, 2023
- 9.3.4. Thermo Fisher Scientific (Patheon)
- 9.3.4.1. Overview
- 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.4.3. Product Benchmarking
- 9.3.4.4. Strategic Initiatives
- 9.3.5. Catalent, Inc.
- 9.3.5.1. Overview
- 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.5.3. Product Benchmarking
- 9.3.5.4. Strategic Initiatives
- 9.3.6. Parexel International (MA) Corporation
- 9.3.6.1. Overview
- 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.6.3. Product Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Almac Group
- 9.3.7.1. Overview
- 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.7.3. Product Benchmarking
- 9.3.7.4. Strategic Initiatives
- 9.3.8. Marken
- 9.3.8.1. Overview
- 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.8.3. Product Benchmarking
- 9.3.8.4. Strategic Initiatives
- 9.3.9. Piramal Pharma Solutions
- 9.3.9.1. Overview
- 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.9.3. Product Benchmarking
- 9.3.9.4. Strategic Initiatives
- 9.3.10. UDG HEALTHCARE
- 9.3.10.1. Overview
- 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.10.3. Product Benchmarking
- 9.3.10.4. Strategic Initiatives
- 9.3.11. DHL
- 9.3.11.1. Overview
- 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.11.3. Product Benchmarking
- 9.3.11.4. Strategic Initiatives
- 9.3.12. FedEx
- 9.3.12.1. Overview
- 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.12.3. Product Benchmarking
- 9.3.12.4. Strategic Initiatives
- 9.3.13. Movianto
- 9.3.13.1. Overview
- 9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.13.3. Product Benchmarking
- 9.3.13.4. Strategic Initiatives
- 9.3.14. Packaging Coordinators Inc
- 9.3.14.1. Overview
- 9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.3.14.3. Product Benchmarking
- 9.3.14.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook